<ul>
	<li>Hemorrhage: Do not administer Cabozantinib if recent history of hemorrhage.</li>
	<li>Perforations and Fistulas: Monitor for symptoms. Discontinue Cabozantinib for unmanageable fistula or GI perforation.</li>
	<li>Thrombotic Events: Discontinue Cabozantinib for myocardial infarction, cerebral infarction, or other serious thromboembolic events.</li>
	<li>Hypertension and Hypertensive Crisis: Monitor blood pressure regularly. Interrupt for hypertension that is not adequately controlled with anti-hypertensive therapy. Discontinue Cabozantinib for hypertensive crisis or severe hypertension that cannot be controlled with</li>
	<li>anti-hypertensive therapy.</li>
	<li>Diarrhea: May be severe. Interrupt Cabozantinib immediately until diarrhea resolves or decreases to Grade 1. Recommend standard antidiarrheal treatments.</li>
	<li>Palmar-plantar erythrodysesthesia (PPE): Interrupt Cabozantinib treatment until PPE resolves or decreases to Grade 1.</li>
	<li>Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome.</li>
	<li>Osteonecrosis of the jaw: Withhold Cabozantinib for at least 28 days prior to invasive dental procedures and for development of ONJ.</li>
	<li>Wound complications: Withhold Cabozantinib for dehiscence or complications requiring medical intervention.&nbsp;</li>
	<li>Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue Cabozantinib.</li>
	<li>Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 4 months after the last dose.</li>
</ul>